Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery

Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and MOLCURE Inc., announced they generated potent, binding antibodies to an undisclosed oncology target for Twist’s internal pipeline of antibody candidates. The collaborative research project resulted from a technology agreement between the companies to pursue novel antibody targets through Twist’s antibody discovery and optimization together with MOLCURE’s AI technology.

“We are proud to have engaged in collaborative research with Twist Bioscience, selected by Fast Company as one of the most innovative companies in 2021,” said Ryu Ogawa, Ph.D., CEO of MOLCURE. “Our expectations that this would reinforce our partner’s therapeutic antibody pipelines and further strengthen our AI driven molecule design service were confirmed in this project.”

“Twist Bioscience continues to innovate and incorporate the most advanced methods of antibody discovery and optimization into our processes,” said Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “MOLCURE’s AI approach complements our proprietary antibody discovery and optimization efforts, leveraging technology to refine our internal antibody pipeline. Their platform enables us to find more leads derived from NGS sequencing from our library. We look forward to taking leads generated from this collaboration forward within our internal pipeline.”

About MOLCURE Inc.

MOLCURE is a growing startup company with a unique biopharmaceutical molecular design technology making full use of Artificial Intelligence (AI). MOLCURE’s patented and validated AI platform is based on evolutionary molecular engineering, next-generation sequencing (NGS), and laboratory automation technologies. MOLCURE is contributing to the development of innovative biopharmaceuticals by creating high-performance drug molecules challenging to develop with traditional technologies.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody  libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Advertisement